



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 152 898

B1

⑫

EUROPEAN PATENT SPECIFICATION

⑯ Date of publication of patent specification: **17.01.90**

⑮ Int. Cl.⁵: **A 61 K 9/50**

⑰ Application number: **85101490.2**

⑲ Date of filing: **12.02.85**

④ Process for encapsulation and encapsulated active material system(.

⑩ Priority: **15.02.84 US 580394**

⑬ Date of publication of application:
28.08.85 Bulletin 85/35

⑭ Publication of the grant of the patent:
17.01.90 Bulletin 90/03

⑮ Designated Contracting States:
CH DE FR GB IT LI

⑯ References cited:
EP-A-0 052 829
DE-A-3 306 259
GB-A-2 094 750
GB-A-2 094 833
GB-A-2 119 737
GB-A-2 119 737
US-A-4 487 758

⑰ Proprietor: **MASSACHUSETTS INSTITUTE OF TECHNOLOGY**
77 Massachusetts Avenue
Cambridge, MA 02139 (US)

⑰ Inventor: **Rha, ChoKyun**
285 Commonwealth Ave
Boston Massachusetts 02115 (US)
Inventor: **Rodriguez-Sanchez, Dolores**
4093 N.W. Walnut Place
Corvallis Oregon 97330 (US)

⑰ Representative: **Patentanwälte Zellentin & Partner**
Zweibrückenstrasse 15
D-8000 München 2 (DE)

EP 0 152 898 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

EP 0 152 898 B1

Description

This invention relates to a process for encapsulating biologically active materials such as cells or tissues or biochemically or chemically active compositions and to the capsule including the active materials.

In biochemical production and biotechnological applications, health and viability of active materials such as cells and microorganisms, is important since these active materials are capable of producing biologically or biochemically active components that find a wide variety of use. For example, cells are capable of producing antibodies, hormones, lymphokines, antibiotics, interferons and other biochemicals or chemicals. Mammalian cell lines are grown by being surrounded by an aqueous medium containing a nutrient in order to promote the viability and growth of the cells and enables continued production of the desired microbiological or biological products. It has been proposed to utilize so-called microcarriers, which are beads having the appropriate charge and exchange capacity to promote the growth of the cells thereon in an efficient manner. The microcarriers themselves are maintained in an aqueous suspension containing the proper nutrient composition to promote cell growth and production of the desired microbiological product.

Biological products which are shed or excreted from the cells become admixed with the aqueous suspending composition, which in many cases, is at very dilute concentrations. The subsequent recovery of the desired product is thereby rendered difficult and time consuming.

In order to overcome problems associated with microbiological product recovery, it has been proposed to encapsulate cells or microorganisms within a membrane which permits nutrients to be metabolized by the cell or microorganism while retaining the microbiological product produced by the cell or microorganism within the encapsulating membrane. Such processes are disclosed, for example, in US—A—4,409,331 and 4,352,883. The semipermeable membrane surrounding the biologically-active material has a selected permeability so that substances having a certain molecular weight or below, are allowed to pass through the semi-permeable membrane. By controlling the permeability of the membrane, and by having a knowledge of the approximate molecule size of the desired product, one can confine the product, within the space between the active material and the semi-permeable membrane.

Unfortunately, the process described in US—A—4,409,331 and 4,352,883 require that the membrane be formed from the surface of an initially formed solid gel bead. This requires that the interior of the bead be subsequently liquefied so that the diffusion of nutrient which is required by the microorganism or cell, will not be hindered thereby to promote formation of the desired microbiological product. Furthermore, liquefaction of the gel is highly desired so that the space between the semi-permeable membrane and the microorganism or cell is available for either cell production or products. Typically, these prior art membranes are formed from a cell suspension in alginate solution which is added dropwise to a calcium chloride aqueous solution, thereby to form solid gel beads. The beads then are washed with N-cyclohexylamine ethane sulfonic acid (CHES) and then washed subsequently with sodium chloride. Thereafter, a polylysine solution is added to form a polymer complex with the alginate surface. This surface then is washed with CHES/sodium chloride, subsequently with calcium chloride and then subsequently with sodium chloride. The membrane then is incubated and the gel within the membrane is subsequently liquefied by washing twice with sodium chloride, incubating, washing with sodium citrate and sodium chloride, washing with sodium chloride, and then a final wash. Obviously, such a process for forming encapsulated microbiologically active ingredients is time consuming and difficult and requires a high level of laboratory technique in order to successfully produce the encapsulated cell or microorganism suspended in a liquid medium. Furthermore, during these complicated, time-consuming steps, the viability, productivity or other characteristics of the cell may be altered.

It would be highly desirable to provide a means for encapsulating a microorganism or cell capable of producing a biologically active material which eliminates the necessity of liquefying a solid carrier in order to promote mass transfer into and out of the cell or microorganism. Furthermore, it would be desirable to provide such an encapsulating means which is capable of drastically reducing the number of steps needed to form the encapsulated cell or microorganism. In addition, it would be desirable to provide such an encapsulating means which permits the formation of a membrane capable of having a permeability over a wide range, which permits the isolation or selective separation of a wide variety of biologically or chemically active molecules.

In accordance with this invention, cells, and microorganisms, capable of producing a biologically active composition or biochemicals such as enzymes or hormones or nonbiochemical compositions such as substrates, reactants, or catalysts are encapsulated by a polymer complex comprising the combination of an anionic polymer and a cationic polymer. The term "active material" is used herein to include cells and microorganism which produce a biologically active composition or a composition such as an enzyme, hormone, antibody, antibiotic insecticide, catalyst, substrate or reactant which active material is to be encapsulated in accordance with this invention. The active material is suspended in an aqueous solution of either one of the cationic polymer or the anionic polymer composition. The polymer composition containing the active material then is formed into non gel liquid particles and is added to the other polymer such as in the form of drops from a capillary tube or a spray to form capsules comprising a membrane surrounding a liquid core. The active material is housed within the interior of the membrane suspended in

EP 0 152 898 B1

the liquid core. The capsules then are washed and ready to use or then can be stored in an appropriate medium until use. The permeability of the membrane is controlled by controlling concentration of the cationic and anionic polymers in the solution used in the preparation of the capsule, the pH of the aqueous solutions in which the cationic polymer or anionic polymer are prepared, the presence or absence of counter-ions in each solution, and the molecular weight of the anionic polymer and the cationic polymer as well as the selection of specific polymers.

5 The process of this invention eliminates the need for liquefying the core of the capsule containing the active ingredient and also eliminates the need for multiple washing steps with a variety of reagents which may adversely affect the biological, biochemical or chemical activity of the active ingredient to be encapsulated. In addition, the process of this invention is useful with a wide variety of biologically active molecules over a wide molecular type and weight range, since the permeability of the membrane formed around the capsule can be varied widely. Thus, it is possible to separate, isolate or selectively segregate biologically active compounds of varying nature by controlling the permeability of the membrane.

10 In accordance with this invention, an active material comprising or being capable of producing biologically active compositions is encapsulated within a membrane capable of permitting transport of a variety of compounds such as a nutrient for a cell to the active material and capable of selectively containing, within the membrane, the compound produced. The active ingredient can be a cell, 15 microorganism, tissues or chemical or biochemical reactants. Representative suitable cells include fused cells, e.g. hybridoma cells, or genetically modified cells produced by recombinant DNA technology and lymphocyte cells capable of producing antibodies or microorganisms for fermentation.

20 In addition, microorganisms such as bacteria, can be encapsulated in accordance with this invention. Furthermore, biologically active compositions such as enzymes, hormones, antibiotics or antibodies can be encapsulated so that they can be controllably released through the membrane or retained therein if desired.

25 The encapsulated active ingredient is enclosed by the membrane, which also can contain an aqueous medium which includes nutrients for the active ingredient. The aqueous medium also is capable of dissolving or suspending the microbiologically active material produced by the active ingredient without degrading it. The permeability of the membrane is such as to permit passage of nutrients from a medium surrounding the membrane into the aqueous medium enclosed by the membrane, and so that the 30 microbiologically active composition can be produced by the active ingredient.

35 The active ingredient first is suspended in an aqueous solution of either (a) one or more anionic polymers or (b) one or more cationic polymers. The anionic polymers or cationic polymers chosen are formed of molecularly repetitive segments linked together which here are either positively charged or negatively charged segments distributed along the chain or on substitutions distributed along the chain. 40 The concentration of charged segments is such as to permit electrostatic interaction and entanglement of the polymers when they are contacted together thereby to form the membrane. The resultant suspension then is sprayed into or added dropwise or the like as liquid particles to the other polymer so that a membrane is formed at the interface between the anionic polymer and the cationic polymer. When the interface between the two oppositely charged polymers encloses the active ingredient, the active 45 ingredient thereby becomes encapsulated. Representative suitable anionic polymers include alginate, carragenen, hyaluronic acids, carboxymethylcellulose, xanthan, furcellaran and, sulfonated organic polymers, usually in salt form, e.g. sodium salt. Representative suitable cationic polymers include chitosan, polylysine, polyethylamine and polyvinylamines as well as other amine or imine containing polymer which is capable of coacting with an anionic polymer to form a membrane. The preferred anionic polymers are 50 alginate, or carragenan. The preferred cationic polymers are chitosan, or polylysine. The droplets of the charged polymer containing the active ingredient can be regulated in order to regulate the size of the final encapsulated product. Typical encapsulated products have a size within the range of 50 µm and 5000 µm. When cells are to be encapsulated, the capsule has a size which permits oxygen transfer to those cells that require oxygen for vitality and has a size sufficiently small to afford efficient isolation of the desired cell product, typically between 400 and 800 µm.

55 The permeability of the membrane formed by the interaction of the anionic polymer and the cationic polymer is controlled by controlling the relative concentration of the two oppositely charged polymers, their concentration in the individual aqueous media, the pH of each of the polymer solutions, the molecular weights of the polymers and presence or absence of counter-ions in either of the solutions. By the term "counter-ions" is meant ions which interact with the charged portion of the polymer in order to reduce 60 interaction of that polymer with the oppositely charged polymer. For example, calcium ion interacts with carboxyl ion on the anionic polymer. The calcium ion can be removed with phosphate ion. Increased polymer concentration usually results in decreased permeability. A decrease in the pH of the anionic polymer composition results in increased concentration of hydrogen ion thereby to form reactive cations on the cationic polymers having amine or imine groups. The achievement of a membrane having a desired permeability can be determined by varying the process parameters and incorporating a mixture of compounds of anions molecular weight and size in the droplets or spray. The aqueous medium outside the capsules thus produced can be assigned for the presence of these compounds so that the molecular weight/molecular size cut-off level of the membrane is thus determined.

EP 0 152 898 B1

This invention also provides capsules having a normal membrane structure having improved mechanical properties as compared to the capsules of the prior art. Membranes produced from gel composition and which are subsequently liquified have reduced strength. This is due primarily to the fact that a large proportion of the polymer chains becomes oriented towards the interior of the capsule during gelation rather than in the plane of the membrane. During liquification of the gel, these portions of the polymer chain do not become reoriented into the plane of the membrane and therefore do not contribute to membrane strength. In contrast, in this invention, the ionic portions of the anionic and cationic polymers need not be encumbered with counter ions so that they are free to react with each other along the entire chain length where the different polymers come into reactive contact. By operating in this manner, larger chain lengths of the polymers are oriented in the plane of the membrane. In one particular aspect of this invention, it is possible to have the anionic polymer oriented on the outside of the membrane rather than on the inside of the membrane. Thus, for example, alginate can comprise the outer membrane surface. The result is not possible with prior art processes since the alginate is required to form the initial gel bead. Thus, this invention provides the user with much greater flexibility in forming the capsule. In another particular aspect of this invention, multi-membrane walls can be formed thereby providing membranes with greater strength as compared to capsule of the prior art. This is accomplished by forming the capsule with the anionic polymer chain on the outside of the membrane by the process set forth above. The capsules then are separated from the surrounding aqueous medium by any convenient method such as filtration or centrifugation. The capsules then are mixed with a solution of anionic polymer and a crosslinking divalent metal ion. For example, in the case of alginate as the anionic polymer, calcium ion or barium ion can be used as the crosslinking divalent ion to form an outer membrane of alginate polymer.

After the encapsulated active ingredients are produced in accordance with the above-described process, then they can be separated from the aqueous medium where they are suspended, and then reintroduced into an aqueous medium which contains the nutrients for the active ingredient, so that the microbiologically active compound can be produced. On the other hand, the nutrients can be added to the suspension of encapsulated active ingredients without prior separation thereof.

The following examples illustrate the present invention.

Example I

An alginate solution comprises 0.75 percent—1 percent w/v sodium alginate and 150 mM NaCl was added dropwise to a chitosan solution. The chitosan solution comprised 0.05—0.10 g/dl chitosan, 117 mM NaCl, 0.01 M CaCl₂ and 0.01 M HCl. The chitosan solution had a pH of 6.5. The alginate solution was added dropwise to the chitosan solution to form capsules which were incubated in the chitosan solution for about one minute. Samples of the chitosan solution containing the capsules were separated by centrifugation or by filtration on a centered glass filter, washed with water and transferred separately to a phosphate buffer solution, a saline solution, distilled water or a cell culture medium comprising Dulbecco's Modified Minimum Essential Medium, 5% Fetal Calf Serum and 5% Calf Serum and were found to be surprisingly stable. In addition, the capsules were found to be able to sustain centrifugation at a level at least as high as about 2000 RPM for 10 minutes. In this example, it is preferred that the alginate solution have a viscosity higher than about 0.03 cm²/s (3.0 centistokes) while a chitosan solution preferably has a viscosity of at least about 0.015 cm²/s (1.5 centistokes).

Example II

Following the procedure of Example I, capsules were formed by adding a chitosan solution dropwise to an alginate solution. The Chitosan solution comprised 1.5 percent w/v chitosan, 2.5 percent citric acid and 0.07 M CaCl₂. The alginate solution comprised either 1.1 percent w/v sodium alginate and 0.5 percent sodium sulfate, or a solution comprising 1 percent w/v sodium alginate. As in Example I, the capsules were found to be stable in phosphate buffer, saline, water and cell culture medium, and were able to sustain centrifugation at a level of about 2000 RPM for at least 10 minutes. The core of the capsules is rendered more fluid-like and less solid-like by lowering the concentration of calcium chloride in the chitosan solution.

Example III

Following the procedure of Example I, capsules were formed by adding chitosan solution dropwise in an alginate solution to obtain capsules with a liquid core. The chitosan solution utilized contained between 0.1 percent and 1.5 percent w/v chitosan, 0.05 M NaCl and between 0.006 M and 0.2 M CaCl₂, and a pH rate ranging between 5.5 and 6.6. The alginate solution ranged between 0.1 percent and 1.0 percent sodium alginate.

As in Examples I and II, the capsules produced were found to be stable in phosphate buffer, saline, water and in the cell culture medium. As shown in Table I, the rupture strength of the capsules produced by this invention can be increased by treating them with a divalent ion after they are formed. Alternatively, the divalent ion can be added with an ionic polymer with which it does not interact to form a gel. The diffusion properties can also be controlled by solution conditions which influence the molecular configuration or the charge density of the polymers. The rupture strength of various capsules made in accordance with the procedures set forth in Example III is shown in Table I.

EP 0 152 898 B1

TABLE I
Effect of divalent cations on the rupture strength of the capsules

5	Cation	Capsule preparation	Rupture strength g/cm ²
10	Ca ⁺²	1.35% chitosan, 0.05 N in 0.5% alginate; no treatment of capsules	8
15	Ca ⁺²	Prepared as above+treatment of capsules in 0.1 M CaCl ₂ for 5 minutes	743
20	Ba ⁺²	1.35% chitosan, 0.05 M BaCl ₂ dropped in 0.5% alginate; no further treatment	696
	Ba ⁺²	Prepared as above+treatment of capsules in 0.1 M BaCl ₂ for 5 minutes	1609

Claims

- 25 1. A process for producing a capsule having a liquid core from ionic polymers while avoiding gelation of said core which comprises:
 forming a liquid droplet from an aqueous solution of a first ionic polymer selected from either at least one anionic polymer or at least one cationic polymer and by contacting said droplet with a solution of at least one second ionic polymer, said second ionic polymer having an ionic charge opposite from said first ionic polymer and reacting said first and second polymer in contact with each other thereby to form a membrane encapsulating said droplet.
- 30 2. A process of Claim 1 wherein said droplet contains an active material wherein said active material may be one of the group consisting of living cells or microorganisms or hybridoma cells or lymphocytes or bacteria or a biologically active compound or an enzyme or a hormone.
- 35 3. A process for producing a product from a living cell which comprises encapsulating said cell by the process of Claim 1 and controlling the permeability of said membrane to prevent said product from permeating said membrane, collecting said encapsulated cell, rupturing said membrane and recovering said product, wherein said cell may be either a hybridoma or a lymphocyte cell.
- 40 4. A process of Claim 1, 2 or 3, wherein said anionic polymer is selected from the group consisting of alginate and carragenan and said cationic polymer is selected from chitosan and polylysine.
- 45 5. A process of any one of Claims 1 to 4, wherein a second membrane is formed by cross-linking a second anionic polymer to the anionic polymer portion of said first polymer by adding a divalent metal cation and said second anionic polymer after said first membrane is formed, said metal cation may be selected from calcium, barium and mixtures thereof.
- 50 6. A capsule comprising a polymeric membrane surrounding a liquid core wherein said membrane is formed by the interaction of at least one anionic polymer with at least one cationic polymer and wherein molecular chains comprising said polymer are oriented substantially within said membrane.
- 55 7. The capsule of Claim 6, wherein said cationic polymer forms the inner surface of said membrane adjacent said liquid core.
- 60 8. The capsule of Claim 6, wherein said anionic polymer forms the inner surface of said membrane adjacent said liquid core.
- 65 9. The capsule of Claim 6, wherein said liquid core contains an active material, wherein said active material may be one of the group consisting of living cells, hybridoma cells and lymphocyte cells.
- 70 10. The capsule of any one of Claims 6 to 9, wherein said anionic polymer is selected from alginate and carragenan or wherein said cationic polymer is selected from chitosan and polylysine.
- 75 11. The capsule of any one of Claims 6 to 10, which includes a second membrane formed by cross-linking the anionic polymer to the anionic polymer portion of said polymeric membrane with a divalent metal ion, wherein said divalent metal ion is selected from calcium, barium and mixtures thereof.

60 Patentansprüche

1. Verfahren zur Herstellung einer Kapsel mit einem flüssigen Kern aus ionischen Polymeren unter Vermeidung der Gelatinierung des Kerns, das umfaßt:
 Bildung eines flüssigen Tröpfchens aus einer wässrigen Lösung eines ersten ionischen Polymers,
 65 ausgewählt aus entweder mindestens einem anionischen Polymer oder mindestens einem kationischen

EP 0 152 898 B1

Polymer, und Kontaktierung des Tröpfchens mit einer Lösung aus mindestens einem zweiten ionischen Polymer, wobei das zweite ionische Polymer eine dem ersten ionischen Polymer entgegengesetzt ionische Ladung hat, und Umsetzen des miteinander in Kontakt stehenden ersten und zweiten Polymers, wodurch eine das Tröpfchen einkapselnde Membran gebildet wird.

5 2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß das Tröpfchen ein aktives Material enthält, wobei das aktive Material aus der Gruppe aus lebenden Zellen oder Mikroorganismen oder Hybridomzellen oder Lymphocyten oder Bakterien oder einer biologisch aktiven Verbindung oder einem Enzym oder einem Hormon ausgewählt sein kann.

3. Verfahren zur Herstellung eines Produktes aus einer lebenden Zelle, das umfaßt:

10 Verkapselung der Zelle durch das Verfahren nach Anspruch 1 und Steuerung der Durchlässigkeit der Membran, um zu verhindern, daß das Produkt die Membran durchdringt, Aufbrechen der Membran und Gewinnung des Produkts, worin die Zelle entweder eine Hybridoma- oder eine Lymphocytenzelle sein kann.

15 4. Verfahren nach Anspruch 1, 2 oder 3, worin das anionische Polymer aus der Gruppe bestehend aus Alginat und Carragenan ausgewählt und das kationische Polymer aus Chitosan und Polylysin ausgewählt ist.

20 5. Verfahren nach einem der Ansprüche 1 bis 3, worin eine zweite Membran durch Vernetzung eines zweiten anionischen Polymers mit dem anionischen Polymerteil des ersten Polymers gebildet wird, indem ein zweiwertiges Metallkation und das zweite anionische Polymer nach der Bildung der ersten Membran zugesetzt werden, wobei das Metallkation aus Calcium, Barium und deren Gemischen ausgewählt sein kann.

25 6. Kapsel mit einer einen flüssigen Kern umgebenden polymerischen Membran, worin die Membran durch die Wechselwirkung zwischen mindestens einem anionischen Polymer und mindestens einem kationischen Polymer gebildet wird und worin das Polymer enthaltende Molekularketten im wesentlichen innerhalb der Membran ausgerichtet sind.

7. Kapsel nach Anspruch 6, worin das kationische Polymer die Innenfläche der Membran, angrenzend an den flüssigen Kern, bildet.

8. Kapsel nach Anspruch 6, worin das anionische Polymer die Innenfläche der Membran, angrenzend an den flüssigen Kern, bildet.

30 9. Kapsel nach Anspruch 6, worin der flüssige Kern ein aktives Material enthält, worin das aktive Material ein Material aus der Gruppe bestehend aus lebenden Zellen, Hybridomazellen und Lymphocytenzellen sein kann.

10. Kapsel nach einem der Ansprüche 6 bis 9, worin das anionische Polymer aus Alginat und Carragenan ausgewählt ist oder worin das kationische Polymer aus Chitosan und Polylysin ausgewählt ist.

35 11. Kapsel nach einem der Ansprüche 6 bis 10, die eine zweite Membran enthält, die durch Vernetzung des anionischen Polymers mit dem anionischen Polymerteil der polymerischen Membran mit einem zweiwertigen Metallion gebildet ist, worin das zweiwertige Metallion aus Calcium, Barium und deren Gemischen ausgewählt ist.

40 Revendications

1. Procédé de production d'une capsule ayant un noyau liquide, à partir de polymères ioniques, en évitant la gélification dudit noyau qui comprend:

45 la formation d'une gouttelette liquide à partir d'une solution aqueuse d'un premier polymère ionique choisi parmi soit au moins un polymère anionique soit au moins un polymère cationique et la mise en contact de ladite gouttelette, avec une solution d'au moins un second polymère ionique, ledit second polymère ionique ayant une charge ionique opposée à celle du premier polymère ionique et la réaction dudit premier et second polymère en contact l'un avec l'autre pour former une membrane encapsulant ladite gouttelette.

50 2. Procédé selon la revendication 1 dans lequel ladite gouttelette contient un matériau actif dans lequel ledit matériau actif peut être l'un du groupe constitué de cellules vivantes ou de microorganismes ou de cellules d'hybridomes ou de lymphocytes ou de bactéries ou un composé biologiquement actif ou une enzyme ou une hormone.

55 3. Procédé de production d'un produit à partir d'une cellule vivante qui comprend l'encapsulation de ladite cellule par le procédé de la revendication 1 et le contrôle de la perméabilité de ladite membrane pour empêcher ledit produit de traverser ladite membrane, la récupération de ladite cellule encapsulée et la rupture de ladite membrane et la récupération dudit produit dans lequel ladite cellule peut être soit un hybridome soit une cellule lymphocyte.

60 4. Procédé selon les revendications 1, 2 ou 3, dans lequel ledit polymère anionique est choisi dans le groupe constitué d'alginat de carraghénine et ledit polymère cationique est choisi parmi le chitosane et la polylysine.

65 5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel une seconde membrane est formée par réticulation d'un second polymère anionique avec la portion de polymère anionique dudit premier polymère en additionnant un cation d'un métal divalent et ledit second polymère anionique après

EP 0 152 898 B1

que la première membrane est formée, ledit cation métallique pouvant être choisi parmi le calcium, le baryum et les mélanges de ceux-ci.

6. Capsule comprenant une membrane polymère entourant en noyau liquide, dans laquelle ladite membrane est formée par l'interaction d'au moins un polymère anionique avec au moins un polymère cationique et dans laquelle les chaînes moléculaires comprenant lesdits polymères sont orientés essentiellement à l'intérieur de ladite membrane.

7. Capsule selon la revendication 6, dans laquelle ledit polymère cationique forme la surface interne de ladite membrane adjacente audit noyau liquide.

8. Capsule selon la revendication 6, dans laquelle ledit polymère anionique forme la surface interne de ladite membrane adjacente audit noyau liquide.

9. Capsule selon la revendication 6, dans laquelle ledit noyau liquide contient un matériau actif, lequel matériau actif peut être l'un du groupe consistant en cellules vivantes, cellules d'hybridomes et cellules de lymphocytes.

10. Capsule selon l'une quelconque des revendications 6 à 9, dans laquelle ledit polymère anionique est choisi parmi l'alginate et la carraghénine ou dans laquelle ledit polymère cationique est choisi parmi le chitosane et la polylysine.

11. Capsule selon l'une quelconque des revendications 6 à 10, qui comprend une seconde membrane formée par réticulation d'un polymère anionique vis-à-vis de la portion de polymère anionique de ladite membrane polymère avec un ion d'un métal divalent, ledit ion du métal divalent étant choisi parmi le calcium, le baryum et les mélanges de ceux-ci.

25

30

35

40

45

50

55

60

65